Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Data from pharmacokinetic studies suggest no clinically significant interaction between darunavir/ritonavir and pravastatin. Coadministration of darunavir/ritonavir (800/100 mg once daily) and pitavastatin (2 or 4 mg once daily) was investigated in two studies in HIV-negative subjects. Coadministration with 2 mg pitavastatin decreased pitavastatin AUC and Cmax by 9% and 7% (n=10) and increased darunavir AUC and Cmax by 8% and 3% (n=14). Coadministration with 4 mg pitavastatin decreased pitavastatin AUC and Cmax by 26% and 4% (n=27) and increased darunavir and ritonavir exposure (darunavir AUC and Cmax increased by 3% and 6%; ritonavir AUC and Cmax increased by 8% and 2%).